Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TSVT Stock Forecast 2025-2026
$4.98
Current Price
$261.17M
Market Cap
Buy 0
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to TSVT Price Targets
+0.4%
To High Target of $5.00
+0.4%
To Median Target of $5.00
+0.4%
To Low Target of $5.00
TSVT Price Momentum
-0.2%
1 Week Change
+0.6%
1 Month Change
+16.9%
1 Year Change
+69.4%
Year-to-Date Change
-6.0%
From 52W High of $5.30
+117.5%
From 52W Low of $2.29
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching 2seventy bio (TSVT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TSVT and similar high-potential opportunities.
Latest TSVT Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, TSVT has a neutral consensus with a median price target of $5.00 (ranging from $5.00 to $5.00). Currently trading at $4.98, the median forecast implies a 0.4% upside. This outlook is supported by 0 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Harrison at Morgan Stanley, projecting a 0.4% upside. Conversely, the most conservative target is provided by Matthew Harrison at Morgan Stanley, suggesting a 0.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TSVT Analyst Ratings
0
Buy
3
Hold
0
Sell
TSVT Price Target Range
Low
$5.00
Average
$5.00
High
$5.00
Current: $4.98
Latest TSVT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TSVT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $5.00 |
| Mar 11, 2025 | Leerink Partners | Daina Graybosch | Market Perform | Downgrade | $5.00 |
| Jul 29, 2024 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $6.00 |
| Jun 27, 2024 | Wedbush | David Nierengarten | Neutral | Reiterates | $5.00 |
| May 9, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $11.00 |
| Apr 8, 2024 | Citigroup | Samantha Semenkow | Buy | Maintains | $12.00 |
| Mar 18, 2024 | Wedbush | David Nierengarten | Neutral | Reiterates | $5.00 |
| Jan 31, 2024 | Leerink Partners | Daina Graybosch | Outperform | Upgrade | $18.00 |
| Jan 31, 2024 | TD Cowen | Yaron Werber | Market Perform | Downgrade | $0.00 |
| Nov 20, 2023 | Wedbush | David Nierengarten | Neutral | Downgrade | $2.00 |
| Oct 30, 2023 | Leerink Partners | Daina Graybosch | Market Perform | Downgrade | $0.00 |
| Oct 12, 2023 | Citigroup | Samantha Semenkow | Buy | Initiates | $13.00 |
| Sep 13, 2023 | Guggenheim | Kelsey Goodwin | Neutral | Downgrade | $0.00 |
| Sep 13, 2023 | Goldman Sachs | Salveen Richter | Neutral | Downgrade | $5.00 |
| Sep 12, 2023 | Guggenheim | Kelsey Goodwin | Neutral | Downgrade | $0.00 |
| Aug 15, 2023 | Guggenheim | Kelsey Goodwin | Buy | Maintains | $26.00 |
| Aug 15, 2023 | Goldman Sachs | Salveen Richter | Buy | Maintains | $24.00 |
| Jul 28, 2023 | Morgan Stanley | Matthew Harrison | Equal-Weight | Downgrade | $13.00 |
| Jul 28, 2023 | Wedbush | David Nierengarten | Outperform | Maintains | $22.00 |
| Jul 20, 2023 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $25.00 |
2Seventy Bio Inc. (TSVT) Competitors
The following stocks are similar to 2seventy bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TSVT
2seventy bio
mkt cap
261.17M
2Seventy Bio Inc. (TSVT) Financial Data
2Seventy Bio Inc. has a market capitalization of $261.17M with a P/E ratio of -4.5x. The company generates $37.86M in trailing twelve-month revenue with a -151.2% profit margin.
Revenue growth is -72.6% quarter-over-quarter, while maintaining an operating margin of -789.3% and return on equity of -24.6%.
Valuation Metrics
Market Cap
$261.17M
Enterprise Value
$329.61M
P/E Ratio
-4.5x
PEG Ratio
-11.6x
Price/Sales
6.9x
Growth & Margins
Revenue Growth (YoY)
-72.6%
Gross Margin
-202.2%
Operating Margin
-789.3%
Net Margin
-151.2%
EPS Growth
-72.6%
Financial Health
Cash/Price Ratio
+67.0%
Current Ratio
4.7x
Debt/Equity
115.6x
ROE
-24.6%
ROA
-12.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
2Seventy Bio Inc. (TSVT) Business Model
About 2Seventy Bio Inc.
What They Do
Develops cell and gene therapies for cancer.
Business Model
The company generates revenue through the research and development of innovative immunotherapy solutions that modify patients' cells to better combat cancer. By focusing on personalized medicine, it aims to create effective therapies that can be commercialized once they meet regulatory approval.
Additional Information
2Seventy Bio is positioned within the rapidly growing biotechnology sector, emphasizing advancements in genetic engineering and oncology. Their mission is to lead in cancer treatment innovations, which could significantly impact patient outcomes and the future of cancer therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
65
CEO
Mr. William D. Baird III, M.B.A.
Country
United States
IPO Year
2021
Website
www.2seventybio.com2Seventy Bio Inc. (TSVT) Latest News & Analysis
Latest News
Quick Summary
Kahn Swick & Foti is investigating the proposed sale of 2seventy bio, Inc. to Bristol Myers Squibb, offering $5.00 per share. They aim to assess the fairness of the transaction process.
Why It Matters
The investigation into 2seventy bio's sale to Bristol Myers Squibb may signal potential issues with the deal's valuation or process, impacting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
2seventy bio, Inc. (Nasdaq: TSVT) reported its Q4 and full-year 2024 results, highlighting a strategic focus on Abecma, the first FDA-approved anti-BCMA CAR T cell therapy.
Why It Matters
2seventy bio's streamlined focus on Abecma and recent financial results signal potential for improved profitability, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
2seventy bio, Inc. (TSVT) has received a Zacks Rank #2 (Buy) upgrade, indicating increased optimism regarding its earnings potential, which may lead to a rise in stock price.
Why It Matters
The Zacks Rank #2 upgrade signals positive earnings outlook for 2seventy bio, Inc. (TSVT), likely boosting investor confidence and driving the stock price up.
Source: Zacks Investment Research
Market Sentiment:
Positive
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT
1 month ago
Quick Summary
Monteverde & Associates PC is investigating 2seventy bio, Inc. (NASDAQ: TSVT) regarding its proposed merger with Bristol Myers Squibb, following its recognition as a top firm in class action recovery.
Why It Matters
The investigation into 2seventy bio, Inc. regarding its merger with Bristol Myers Squibb may signal potential legal risks or financial implications for shareholders, impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the fairness of Bristol Myers Squibb's $5.00 per share acquisition of 2seventy bio, Inc. (NASDAQ: TSVT) for its shareholders.
Why It Matters
The investigation into the fairness of 2seventy bio's sale price could impact shareholder sentiment and stock value, signaling potential legal risks or financial discrepancies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating 2seventy bio (TSVT) for potential fiduciary duty breaches related to its $5.00 per share cash transaction with Bristol Myers Squibb.
Why It Matters
The investigation into 2seventy bio for potential fiduciary breaches could indicate legal risks and financial implications, impacting shareholder confidence and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About TSVT Stock
What is 2Seventy Bio Inc.'s (TSVT) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, 2Seventy Bio Inc. (TSVT) has a median price target of $5.00. The highest price target is $5.00 and the lowest is $5.00.
Is TSVT stock a good investment in 2025?
According to current analyst ratings, TSVT has 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TSVT stock?
Wall Street analysts predict TSVT stock could reach $5.00 in the next 12 months. This represents a 0.4% increase from the current price of $4.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is 2Seventy Bio Inc.'s business model?
The company generates revenue through the research and development of innovative immunotherapy solutions that modify patients' cells to better combat cancer. By focusing on personalized medicine, it aims to create effective therapies that can be commercialized once they meet regulatory approval.
What is the highest forecasted price for TSVT 2Seventy Bio Inc.?
The highest price target for TSVT is $5.00 from Matthew Harrison at Morgan Stanley, which represents a 0.4% increase from the current price of $4.98.
What is the lowest forecasted price for TSVT 2Seventy Bio Inc.?
The lowest price target for TSVT is $5.00 from Matthew Harrison at Morgan Stanley, which represents a 0.4% increase from the current price of $4.98.
What is the overall TSVT consensus from analysts for 2Seventy Bio Inc.?
The overall analyst consensus for TSVT is neutral. Out of 9 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are TSVT stock price projections?
Stock price projections, including those for 2Seventy Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 7:32 AM UTC